Cepheid Launches New Test - Analyst Blog
August 15 2011 - 5:40AM
Zacks
Recently, Cepheid (CPHD) released the updated
Xpert BCR-ABL Monitor test in Europe. The test that runs on
the company’s GeneXpert system detects the BCR-ABL mRNA transcript
in the peripheral blood of patients with Chronic Myelogenous
Leukemia (CML) in two hours. CML is a cancer of the white blood
cells. If left untreated, the disease deteriorates and approaches
the blastic phase where survival is limited.
Cepheid currently offers 11 tests in the US and 12 outside the
US. Although the company is one of the leading players in the
Healthcare Associated Infections (HAI) segment, it is also looking
at expanding in non-HAI markets, which include critical infectious
diseases, women’s health, and oncology and genetics.
Additional tests under development in the areas of HIV, HCV and
HPV are targeted for release in Europe within the 2012-2013
timeframe. The company is also targeting up to 7 CLIA waived tests
by the end of 2016, which would significantly expand the market
potential of the GeneXpert system beyond the hospital market.
Successful commercialization of these tests should further improve
Cepheid’s top line going forward.
Based on a wide test menu, Cepheid has recorded robust growth in
its system placement over the past few quarters. The company placed
the maximum number of systems during the reported quarter in its
history bringing the total number of systems placed globally to
2,224. Excluding HBDC, the company placed 148 GeneXpert systems
during the quarter with 79 placements in North America and 69 in
the international market.
Within the Clinical business, Cepheid recorded a 53%
year-over-year growth in systems sales to $13.2 million and a 14%
rise on a sequential basis. International system placements were
driven by strong performance in Germany, ahead of the new infection
control law that is to take effect at the end of March 2012.
However, the company faces tough competition from other players
in the diagnostic market such as Laboratory Corporation of
America Holdings (LH) and Quest
Diagnostics (DGX).
We currently have an Outperform recommendation on Cepheid.
CEPHEID INC (CPHD): Free Stock Analysis Report
QUEST DIAGNOSTC (DGX): Free Stock Analysis Report
LABORATORY CP (LH): Free Stock Analysis Report
Zacks Investment Research
Cepheid (NASDAQ:CPHD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cepheid (NASDAQ:CPHD)
Historical Stock Chart
From Sep 2023 to Sep 2024